The Europe gastrointestinal drugs market size is expected to reach US$ 34,299.35 million by 2031 from US$ 19,650.29 million in 2023. The market is estimated to record a CAGR of 7.2% from 2023 to 2031.
Executive Summary and Europe Gastrointestinal Drugs Market Analysis:
The Europe gastrointestinal drugs market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The market growth in the region is attributed to the rising prevalence of gastrointestinal disorders such as IBD and IBS, along with a surge in research and development activities, leading to the innovation of advanced therapeutics for the treatment of various gastrointestinal conditions.
Europe Gastrointestinal Drugs Market Strategic Insights
Key segments that contributed to the derivation of the gastrointestinal drugs market analysis are drug class, application, route of administration, and distribution channel.
- Based on drug class, the Europe gastrointestinal drugs market is segmented into biologics, antidiarrheal and laxatives, acid neutralizers, anti-inflammatory drugs, antiemetic and antinauseants and others. The biologics held the largest share of the market in 2023.
- By application, the Europe gastrointestinal drugs market is segmented into irritable bowel syndrome, inflammatory ulcerative colitis, Crohn’s disease, gastroenteritis, celiac disease and others. The irritable bowel syndrome segment held the largest share of the market in 2023.
- By route of administration, the Europe gastrointestinal drugs market is bifurcated into oral and parenteral. The oral segment held a larger share of the market in 2023.
- By distribution channel, the Europe gastrointestinal drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share of the market in 2023.
Europe Gastrointestinal Drugs Market Outlook
Gastrointestinal diseases are conditions that occur in the gastrointestinal tract. Common digestive problems include heartburn, inflammatory bowel diseases (IBD), inflammatory bowel syndrome (IBS), gastroenteritis, gastroesophageal reflux disease (GERD), constipation, diarrhea, etc. Gastrointestinal diseases are common chronic inflammatory conditions that affect an enormous population worldwide. This is due to a sedentary lifestyle, changing dietary habits, and stress, among other factors. Also, the incidence and prevalence of gastrointestinal diseases are higher in adults, and as the population ages, the disease burden is also expected to increase.
According to the study, “Gastroesophageal Reflux Disease,” published in July 2023, GERD is one of the most prevalent diagnosed gastrointestinal conditions, affecting 20% of the people, resulting in major economic burden in direct and indirect costs and adversely impacting the quality of life.
Europe is also experiencing a growing number of chronic digestive diseases due to the aging population and lifestyle factors such as a surge in obesity cases and high alcohol consumption. According to the European Federation of Crohn's & Ulcerative Colitis Associations, ~10 million individuals are suffering from IBD worldwide. Research conducted by Crohn’s & Colitis UK in 2022 indicates that 1 in every 123 people are either diagnosed with Crohn’s disease or ulcerative colitis in the UK, representing a total of half a million people in the country suffering from IBD.
Furthermore, the incidence and prevalence of IBS have increased in the last few decades globally. As per the International Foundation for Gastrointestinal Disorders, Inc., IBS is the most prevalent functional gastrointestinal disease, with a prevalence rate of 10–15% of the population across the globe. A study conducted by the University of Gothenburg states that for every ten adults in the world, four suffer from functional gastrointestinal disorders of varying severity. In the US, there are approximately 2.4–3.5 million hospital visits for IBS annually. Thus, the rising prevalence of gastrointestinal diseases worldwide fuels the demand for treatment of these conditions, thereby driving the gastrointestinal drugs market.
Europe Gastrointestinal Drugs Market Country Insights
Based on country, the Europe gastrointestinal drugs market comprises Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany held the largest share in 2023.
Germany is an attractive market for gastrointestinal drugs market due to the increasing prevalence of gastrointestinal infections and disorders. As per the article published by Deutsches Ärzteblatt 2023, the prevalence of inflammatory bowel disease is rapidly increasing and affecting 0.7% of the German population or 600,000 patients in Germany. Additionally, as per a medRxiv article published in 2023, Gastrointestinal infections account for 24.5 million outpatient visits annually in Germany. Moreover, the surging development of effective treatment options by various market players led to innovative product developments and clinical trials, along with the increasing geriatric population prone to gastrointestinal issues, are contributing to the market growth. For instance, in October 2021, Renexxion Ireland Ltd. collaborated with Dr. Falk Pharma GmbH for the development and commercialization of Naronapride, a unique late-stage GI prokinetic, initially for gastroparesis. Furthermore, Germany is Europe’s largest pharmaceutical market, and constant expansion in the coming years is expected to be a major contributor to the market growth. As per the Germany Trade and Invest, Germany's pharmaceutical production volume reached US$ 38.03 billion by the end of 2021, with a growth rate of 6.9% per year. In addition, Germany has invested US$ 9.56 billion in research and development, with 589 clinical trials in 2021, ranking second in Europe and sixth worldwide. Therefore, all the above-discussed factors are expected to fuel the growth of the gastrointestinal drugs market in Germany during the forecast period.
Europe Gastrointestinal Drugs Market Report Highlights
| Report Attribute | Details |
| Market size in 2023 | US$ 19,650.29 Million |
| Market Size by 2031 | US$ 34,299.35 Million |
| CAGR (2023 - 2031) | 7.2% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Drug Class
|
|
Regions and Countries Covered
|
|
| Europe | UK, Germany, France, Italy, Spain, Rest of Europe |
| Market leaders and key company profiles |
|
Some of the key players operating in the gastrointestinal drugs market include Sanofi SA, GSK Plc, Johnson & Johnson, Bausch Health Companies Inc, AstraZeneca Plc, Takeda Pharmaceutical Co Ltd, AbbVie Inc, Bayer AG, and Pfizer Inc among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.
Europe Gastrointestinal Drugs Market Research Methodology :
The following methodology has been followed for the collection and analysis of data presented in this report:
- Secondary Research
The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:
- Company websites, annual reports, financial statements, broker analyses, and investor presentations.
- Industry trade journals and other relevant publications.
- Government documents, statistical databases, and market reports.
- News articles, press releases, and webcasts specific to companies operating in the market.
Note: All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.
- Primary Research
The Insight Partners’ conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis, and gain valuable insights. These research interviews are designed to:
- Validate and refine findings from secondary research.
- Enhance the expertise and market understanding of the analysis team.
- Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects.
Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:
- Industry stakeholders: Vice Presidents, business development managers, market intelligence managers, and national sales managers
- External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise
Europe Gastrointestinal Drugs Market Country and Regional Insights
